#United States #Los Angeles #AES 2024 #Upsher-Smith #Vigabatrin

Upsher-Smith to Highlight Groundbreaking Epilepsy Treatments at AES 2024

Upsher-Smith Laboratories, LLC is gearing up to showcase its advancements in epilepsy treatment at the upcoming Annual Meeting of the American Epilepsy Society (AES) 2024, set to take place from December 6 to December 10 in Los Angeles, California. This year, the company will present pivotal data on their innovative vigabatrin formulations, specifically focused on the treatment of infantile spasms.

Event Overview

As a highlight of the AES meeting, Upsher-Smith will engage participants with several presentations, including the Innovation Pavilion sessions. Attendees can expect detailed discussions on the use of vigabatrin, an important drug for managing pediatric patients with this challenging condition.

Clinical Significance of VIGAFYDE™

The spotlight will be on VIGAFYDE™ (vigabatrin) Oral Solution, a recently acquired formulation added to Upsher-Smith's expanding rare disease portfolio through the acquisition of Pyros Pharmaceuticals Inc. This particular formulation is not only unique as the first and only ready-to-use vigabatrin oral solution but is also critical as a monotherapy treatment for infantile spasms in children aged one month to two years. Given that it comes with the first new drug application approval for this condition in 15 years, it marks a significant development in therapeutic options, allowing for personalized treatment tailored to the needs of patients and their caregivers.

The acquisition of VIGAFYDE™ strengthens Upsher-Smith's commitment to the rare disease community and provides healthcare practitioners with enhanced choices when managing these vulnerable pediatric patients.

Innovation Pavilion Presentations

At the Innovation Pavilion, which will be open from December 7 to December 9, Upsher-Smith will lead discussions from 12:30 PM to 1:30 PM each day. Key topics will revolve around:

• - Dissolution and Stability of Vigabatrin: This presentation, scheduled for December 8, aims to explore the efficacy of vigabatrin powder when dissolved in various liquids, such as water, fruit juice, and milk.
• - Comparison of VIGAFYDE™ to Other Formulations: Another key presentation will delve into caregiver reports comparing the newly introduced oral solution and SABRIL® powder form of vigabatrin, assessing their effectiveness in treating infantile spasms.

Supporting Patients and Caregivers

Upsher-Smith has always placed a strong emphasis on patient support through its Promise of Support™ Program. This initiative aims to assist patients and their caregivers throughout the treatment journey, offering a wide range of resources for ensuring uninterrupted medication supply, access to vital educational materials, and support with prior authorizations.

Since its launch nearly a decade ago, the program has facilitated connections between families and healthcare providers, ensuring that patients receive the high-quality care they deserve. Financial assistance options are also available to eligible patients, helping to alleviate the financial burden often associated with continuous medication needs.

The Importance of Risk Evaluation and Mitigation Strategy (REMS)

It is crucial for healthcare providers to remain aware of the serious risks associated with vigabatrin, including the potential for permanent vision loss. Under the FDA-directed Vigabatrin Risk Evaluation and Mitigation Strategy (REMS), both patients and providers must engage in careful risk assessment before initiating treatment.

Conclusion

The upcoming AES 2024 meeting presents a prime opportunity for Upsher-Smith to reinforce its commitment to improving treatment for patients with epilepsy, particularly children battling infantile spasms—a condition that requires immediate and effective intervention. The introduction of VIGAFYDE™ showcases the potential for innovative therapies in providing better health outcomes and quality of life for those affected. Participants are encouraged to visit the Upsher-Smith booths to learn more about their offerings and engage with company representatives.

For further information on Upsher-Smith and their product portfolio, please visit Upsher-Smith’s official website.